J&J’s COVID-19 Vaccine Booster May Best Pfizer’s, Says Study

A booster dose of the Johnson & Johnson (J&J) COVID-19 vaccine proved just as effective — or possibly more effective — for patients inoculated with the Pfizer-BioNTech vaccine as a booster with two doses of the Pfizer vaccine in a phase 2 study.

Funded in part by J&J, the small study at the Beth Israel Deaconess Medical Center in Boston, Mass., included just 24 participants.

The researchers found that a J&J booster increased neutralizing antibodies comparably to a Pfizer/BioNTech booster. But the findings also suggested a J&J booster increased T-cell responses more than an additional Pfizer/BioNTech dose.